Sign In
Buy WXXWY
$8.21
-0.700 (-7.86%)
At Close: Jun 03, 2026
WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year
04:30am, Thursday, 02'nd Jan 2025
Named for second consecutive year named to prestigious DJSI list Leading green biologics solutions for a healthier future SHANGHAI , Jan. 2, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK),
WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
03:30am, Thursday, 12'th Dec 2024
Leading Green CRDMO Driven by Innovation for a Healthier Future Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI , Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bi
WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000L PPQ Success and HPRA GMP Authorizations
07:19pm, Thursday, 05'th Dec 2024
Multiple successful 16,000L PPQ runs highlight that disposable manufacturing can achieve similar performance as traditional stainless reactors GMP Authorizations by HPRA demonstrate that new global si
WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line
11:00pm, Wednesday, 13'th Nov 2024
LEVERKUSEN, Germany , Nov. 13, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it wi
WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development
05:00am, Monday, 28'th Oct 2024
SHANGHAI , Oct. 28, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced the launch of W
WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year
08:00am, Wednesday, 16'th Oct 2024
HONG KONG , Oct. 16, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has rec
WuXi Biologics Included in Hang Seng ESG 50 Index
05:30am, Monday, 23'rd Sep 2024
HONG KONG , Sept. 23, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that it has be
By leveraging its ultra-intensified fed-batch platform, WuXiUI™, WuXi Biologics has completed its first scale-up to 2,000L drug substance (DS) GMP manufacturing, achieving a 4-fold productivity imp
WuXi Biologics (Cayman) Inc. (WXXWY) Q2 2024 Earnings Call Transcript
02:52pm, Thursday, 22'nd Aug 2024
WuXi Biologics (Cayman) Inc. (OTCPK:WXXWY) Q2 2024 Earnings Conference Call August 22, 2024 8:30 AM ET Company Participants Lina Fan - Senior Vice President, Head of Investor Relations Chris Chen - Ch
WuXi Biologics Reports Solid 2024 Interim Results
11:46am, Wednesday, 21'st Aug 2024
Revenue increased by 1.0% YoY to RMB 8,574.2 million Non-COVID revenue grew by 7.7% YoY, with non-COVID late-phase & commercial manufacturing YoY growth of 11.7%Added 61 new integrated projects, inc
WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
04:00am, Thursday, 08'th Aug 2024
Partnership leverages Medigene's leadership for T cell receptor (TCR) generation and characterization and WuXi Biologics' unique anti-CD3 mAb, its T cell engager (TCE) platform and proprietary bispeci
Medigene and WuXi Biologics Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers
04:00am, Thursday, 08'th Aug 2024
Planegg/Martinsried, August 8, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard) and WuXi Biologics (stock code: 2269.HK) enter into a three-year, multi-target strategic partnership to design an
WUXI and SUZHOU, China , Aug. 1, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced t
WuXi Biologics Named Constituent of the FTSE4Good Index Series for Fourth Year
01:30am, Wednesday, 10'th Jul 2024
SHANGHAI , July 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has again been name
WuXi Biologics Releases 2023 ESG Report Demonstrating Strong Sustainability Commitment
10:55pm, Monday, 29'th Apr 2024
The Company demonstrated a deep commitment to achieving ESG success in partnership with global clients, creating long-term value for all stakeholders. The Company made remarkable progress in tackling
